65 related articles for article (PubMed ID: 23769878)
21. Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.
Zhuang J; Yu Y; Li Z; Lu S
Oncotarget; 2017 Aug; 8(32):53675-53683. PubMed ID: 28881841
[TBL] [Abstract][Full Text] [Related]
22. Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection.
Fan L; Yang H; Yao F; Zhao Y; Gu H; Han K; Zhao H
Onco Targets Ther; 2017; 10():239-245. PubMed ID: 28123305
[TBL] [Abstract][Full Text] [Related]
23. Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods.
Shi X; Wu H; Lu J; Duan H; Liu X; Liang Z
Sci Rep; 2016 Feb; 6():22297. PubMed ID: 26923333
[TBL] [Abstract][Full Text] [Related]
24. A Nation-Wide Cancer Registry-Based Study of Adenosquamous Carcinoma in Taiwan.
Lan YT; Huang KH; Liu CA; Tai LC; Chen MH; Chao Y; Li AF; Chiou SH; Shyr YM; Wu CW; Fang WL
PLoS One; 2015; 10(10):e0139748. PubMed ID: 26445240
[TBL] [Abstract][Full Text] [Related]
25. Molecular profiling of lung adenosquamous carcinoma: hybrid or genuine type?
Vassella E; Langsch S; Dettmer MS; Schlup C; Neuenschwander M; Frattini M; Gugger M; Schäfer SC
Oncotarget; 2015 Sep; 6(27):23905-16. PubMed ID: 26068980
[TBL] [Abstract][Full Text] [Related]
26. Surgical specimen histology revealed inadequacy of conventional transbronchial needle aspiration sample in the diagnosis of adenosquamous lung carcinoma.
Chen J; Gao YD; Cao Y; Yang J; Luo GW
J Thorac Dis; 2015 Apr; 7(4):680-6. PubMed ID: 25973234
[TBL] [Abstract][Full Text] [Related]
27. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
28. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
29. Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Kim MH; Kim HR; Cho BC; Bae MK; Kim EY; Lee CY; Lee JS; Kang DR; Kim JH
Lung Cancer; 2014 May; 84(2):196-202. PubMed ID: 24629638
[TBL] [Abstract][Full Text] [Related]
30. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
31. Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Lu RL; Hu CP; Yang HP; Li YY; Gu QH; Wu L
Pathol Oncol Res; 2014 Apr; 20(2):445-51. PubMed ID: 24297623
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Cho KM; Keam B; Kim TM; Lee SH; Kim DW; Heo DS
Korean J Intern Med; 2015 Nov; 30(6):891-8. PubMed ID: 26552465
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Song Z; Lin B; Shao L; Zhang Y
J Chin Med Assoc; 2013 Sep; 76(9):481-5. PubMed ID: 23769878
[TBL] [Abstract][Full Text] [Related]
34. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Rosell R; Viteri S; Molina MA; Benlloch S; Taron M
Curr Opin Oncol; 2010 Mar; 22(2):112-20. PubMed ID: 19949333
[TBL] [Abstract][Full Text] [Related]
35.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
36.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
